Biodexa Pharmaceuticals (BDRX) Research & Development (2013 - 2025)

Biodexa Pharmaceuticals has disclosed Research & Development across 12 years of filings, most recently posting -$2.2 million for Q2 2025.

• In Q2 2025, Research & Development changed N/A year-over-year to -$2.2 million; the TTM figure through Jun 2025 stood at -$12.9 million (changed N/A YoY), while the FY2025 annual figure was -$5.2 million, up 24.85% from the prior year.
• Research & Development came in at -$2.2 million for Q2 2025 at Biodexa Pharmaceuticals, up from -$2.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of -$2.2 million in Q2 2025 to a low of -$6.3 million in Q4 2021.
• Average Research & Development over 5 years is -$3.9 million, with a median of -$2.9 million recorded in 2022.
• Year-over-year, Research & Development jumped 44.4% in 2021 and declined 6.85% in 2022.
• Over 5 years, Research & Development stood at -$6.3 million in 2021, then grew by 4.44% to -$6.0 million in 2022, then rose by 15.8% to -$5.0 million in 2023, then surged by 44.34% to -$2.8 million in 2024, then gained by 20.94% to -$2.2 million in 2025.
• Per Business Quant data, the three most recent Research & Development figures were -$2.2 million in Q2 2025, -$2.8 million in Q4 2024, and -$5.0 million in Q4 2023.